REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

12/03/2019 12:00

RNS Number : 5981S
AstraZeneca PLC
12 March 2019
 


12 March 2019 12:00 GMT
 
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
 
AstraZeneca PLC (the Company) announces that, on 8 March 2019, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.
 



PDMR


Ordinary Shares granted under the AZDBP


Ordinary Shares granted under the AZPSP


Award price per Ordinary Share




Pascal Soriot


9,849


102,475


£62.87




Marc Dunoyer


4,874


48,690


£62.87



 
The AZDBP award represents the portion of each PDMR's annual bonus for 2018 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.
 
The AZPSP award is subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year performance period (1 January 2019 to 31 December 2021). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.
 
Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2018, which is available on the Company's website at www.astrazeneca.com/annualreport2018.
 
 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 
 


Pascal Soriot




2
 


Reason for the notification
 




a)
 


Position/status
 
 


Chief Executive Officer




b)
 


Initial notification /Amendment
 
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 
 


AstraZeneca PLC




b)
 


LEI
 
 


PY6ZZQWO2IZFZC3IOL08




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
 




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 
 


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 




b)
 


Nature of the transaction
 
 


Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan




c)
 


Price(s) and volume(s)
 
 


 



Price(s)
 


Volume(s)




£62.87


112,324



 
 




d)
 


Aggregated information
 
 
- Aggregated volume
 
 
- Price
 
 


Not applicable - single transaction
 
 
 




e)
 


Date of the transaction
 
 


8 March 2019




f)
 


Place of the transaction
 
 


Outside a trading venue



 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 
 


Marc Dunoyer




2
 


Reason for the notification
 




a)
 


Position/status
 
 


Chief Financial Officer




b)
 


Initial notification /Amendment
 
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 
 


AstraZeneca PLC




b)
 


LEI
 
 


PY6ZZQWO2IZFZC3IOL08




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
 




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 
 


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 




b)
 


Nature of the transaction
 
 


Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan




c)
 


Price(s) and volume(s)
 
 


 



Price(s)
 


Volume(s)




£62.87


53,564



 
 




d)
 


Aggregated information
 
 
- Aggregated volume
 
 
- Price
 
 


Not applicable - single transaction
 
 
 




e)
 


Date of the transaction
 
 


8 March 2019




f)
 


Place of the transaction
 
 


Outside a trading venue



 
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 



Media Relations












Gonzalo Viña


UK/Global


+44 203 749 5916




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Jennifer Hursit


UK/Global


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677


















Investor Relations












Thomas Kudsk Larsen






+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharma - Cardiovascular; Metabolism


+44 203 749 5711




Nick Stone


BioPharma - Respiratory; Renal


+44 203 749 5716




Josie Afolabi


Other


+44 203 749 5631




Craig Marks


Finance; Fixed Income


+44 7881 615 764




Jennifer Kretzmann


Retail Investors; Corporate Access


+44 203 749 5824




US toll-free






+1 866 381 72 77



 
 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 
 
 
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHUUARRKNAOAAR